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Abstract
According to a generally accepted concept Lewy-related pathology (LRP) follows hierarchical caudo-rostral progression. LRP 
is also frequently present concomitantly with Alzheimer’s disease (AD), and it has been hypothesized that AD-associated 
LRP forms a distinct type of α-synucleinopathy, where LRP originates in the amygdala. The frequency of distinct forms of 
LRP progression types has not been studied in a population-based setting. We investigated the distribution and progression 
of LRP and its relation to AD pathology and apolipoprotein (APOE) ε4 in a population-based sample of Finns aged over 
85 years (N = 304). Samples from spinal cord to neocortical areas representing 11 anatomical sites without any hierarchical 
selection were analyzed immunohistochemically (α-synuclein antibody clone 5G4). LRP was present in 124 individuals 
(41%) and according to DLB Consortium guidelines 19 of them were categorized as brainstem, 10 amygdala-predominant, 
41 limbic, and 43 diffuse neocortical type, whereas 11 could not be classified. To determine the LRP progression patterns, 
a systematic anatomical scoring was carried out by taking into account the densities of the semiquantitative LRP scores in 
each anatomic site. With this scoring 123 (99%) subjects could be classified into two progression pattern types: 67% showed 
caudo-rostral and 32% amygdala-based progression. The unsupervised statistical K-means cluster analysis was used as a 
supplementary test and supported the presence of two progression patterns and had a 90% overall concordance with the 
systematic anatomical scoring method. Severe Braak NFT stage, high CERAD score and APOE ε4 were significantly (all 
p < 0.00001) associated with amygdala-based, but not with caudo-rostral progression type (all p > 0.2). This population-
based study demonstrates two distinct common LRP progression patterns in the very elderly population. The amygdala-based 
pattern was associated with APOE ε4 and AD pathology. The results confirm the previous progression hypotheses but also 
widen the concept of the AD-associated LRP.
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Introduction
Dementia with Lewy bodies (DLB) is considered the sec-
ond most common primary neurodegenerative disease 
after Alzheimer’s disease (AD) [44, 45]. Its pathologi-
cal hallmark is Lewy-related pathology (LRP) consisting 
of α-synuclein-positive Lewy bodies and neurites [14]. 
The widely used DLB Consortium guidelines [28] clas-
sify LRP into three types based on the extent of LRP in 
the brain—brainstem, limbic or neocortex—following a 
generally accepted concept, suggesting that LRP evolves 
hierarchically, starting in the dorsal medulla oblongata and 
progressing through brainstem to supratentorial structures 
(caudo-rostral progression) [1, 6, 23, 28, 29].
LRP is also frequently present in combination with 
other neurodegenerative diseases, especially AD [38]. 
The LRP pathology in AD is often most severe or even 
restricted to amygdala [2, 11, 18, 43], indicating a devia-
tion from the caudo-rostral progression. Due to this, an 
amygdala-predominant type of LRP was added in the 
newest DLB Consortium guidelines [27]. It has been pro-
posed that AD-associated LRP forms a distinct type of 
α-synucleinopathy, in which LRP arises de novo in the 
amygdala and then progresses to entorhinal cortex, brain-
stem or both [11, 43]. Recent studies, based on a data-
driven cluster analysis, supported this hypothesis [34, 41] 
and an idea of distinct types of LRP progression has also 
been raised by some other studies [3, 13]. It is noteworthy, 
however, that the hypothesis of LRP based in the amyg-
dala is grounded on studies on patients from referral-based 
institutions, and thus these studies may involve selection 
bias. Population- or community-based studies that could 
ascertain the prevalence of the amygdala-based progres-
sion pattern in the general population do not exist.
In this study, we determined LRP in 11 central nervous 
system (CNS) regions in a population-based sample of 304 
individuals aged 85 and older (Vantaa 85+). We report that 
in the very elderly population LRP shows two common 
progression patterns: (1) the caudo-rostral pattern and (2) 
the AD-associated amygdala-based pattern with origin in 
the amygdala.
Materials and methods
Study sample
We evaluated the neuropathologically examined subsam-
ple of the population-based Vantaa 85+ study. The Vantaa 
85+ study consists of all individuals aged at least 85 years 
who had lived in the city of Vantaa (Southern Finland) on 
April 1, 1991. Of the 601 eligible individuals 11 refused to 
participate and one could not be reached. During a 10-year 
follow-up, 565 died and 304 (54%) were autopsied consti-
tuting the neuropathological subsample. The demographic 
details of the neuropathologically studied subsample have 
been previously reported [33] and do not deviate from the 
whole study sample (Supplemental Table 1). The neu-
ropathological subsample consisted of 52 men and 252 
women. Age at death ranged from 85 to 105 years. 196 
of the deceased had been with dementia and 108 without. 
The demographic, neuropathologic and genetic details of 
the subsample with and without dementia are summoned 
in Table 1.
Neuropathological procedures
We assessed α-synuclein pathology using immunohisto-
chemistry with mouse monoclonal anti-α-synuclein anti-
body (clone 5G4, 1:1000, AJ Roboscreen GmbH, Leipzig, 
Germany or Merck KGaA, Darmstadt, Germany) [25]. We 
stained 5 μm tissue sections obtained from 11 anatomic sites 
(sacral and thoracic spinal cord, medulla oblongata, pons, 
midbrain, amygdala, hippocampus from right hemisphere, 
cingulate cortex, frontal cortex, temporal cortex and parietal 
cortex) per individual as previously described [39].
Samples included in this study follow recommendations 
of the DLB Consortium guidelines [27, 28] apart from the 
olfactory bulb and nucleus basalis of Meynert, which were 
not included in the original post-mortem sampling protocol 
of the Vantaa 85+ study. On the other hand, regions of spinal 
cord, not belonging to the DLB guidelines, were included in 
this study and were scored following previously published 
work, in which spinal cord regions were scored equivalently 
to brain regions described in the DLB Consortium guide-
lines [3, 28].
The detailed description of AD pathology of the Vantaa 
85+ study has been reported previously [32, 36, 37]. Briefly, 
the neuritic plaques were assessed by Bielshowsky silver 
stain according to the CERAD protocol [30] and neurofibril-
lary tangles by Gallyas silver stain method according to the 
protocol by Braak and Braak [5]. The neuropathological AD 
diagnosis was determined according to modified National 
Institute on Aging (NIA)/Reagan Institute Consensus Rec-
ommendations for the Postmortem Diagnosis of AD (NIA-
RI) [19]. The neuropathological AD required “moderate” or 
“frequent” plaque scores according to the CERAD protocol 
[30] and Braak NFT stages IV–VI of neurofibrillary pathol-
ogy [5]. The controls were selected from the neuropathologi-
cally examined subpopulation and criteria required neuritic 
plaque score “none” or “sparse” and Braak NFT stage less 
than III. In addition, Lewy neurites in hippocampal CA2-3 
were semiquantitatively assessed as previously recom-
mended [10, 33]. The assessment of the dementia status 
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and analysis of the substantia nigra neuronal loss have been 
previously reported [33].
LRP scoring and classification
First, we scored LRP on a semiquantitative scale (0 = none, 
1 = mild, 2 = moderate, 3 = severe, 4 = very severe) in the 
spinal cord (sacral posterior root entry, sacral anterior horn, 
central canal adjacent to sacral spinal cord and thoracic 
intermediolateral horn of the thoracic spinal cord), medulla 
(dorsal nucleus of vagus), pons (locus coeruleus), midbrain 
(substantia nigra), basal forebrain (amygdala), hippocampus 
(CA2 and transentorhinal cortex), gyrus cinguli, temporal 
cortex, frontal cortex and parietal cortex (Supplemental 
Table 2). We classified individuals into LRP classification 
types presented in the newest DLB guidelines (brainstem, 
amygdala-predominant, limbic and diffuse neocortical) [27]. 
Individuals with LRP in the amygdala and paucity of LRP 
in other brain regions were classified in the amygdala-pre-
dominant type [1, 27, 39]. Individuals that had LRP incom-
parable to any LRP type even after minor modifications (see 
Supplemental material for detailed description) to the DLB 
guidelines were regarded as non-classifiable.
Then, based on LRP scores and LRP classification types, 
we studied if individuals could fit consistently to the previ-
ously hypothesized caudo-rostral and amygdala-based pro-
gression patterns. Thus, the systematic anatomical scoring, 
taking into account differences in density and distribution 
profiles of the semiquantitative LRP scores, was applied. 
Our guidelines for categorizing LRP progression pattern 
according to the systematic anatomical scoring were in brief:
(A) Caudo-rostral pattern was defined by the strongest 
LRP at the medulla and brainstem area, from where 
the pathology spreads through limbic areas to cerebral 
neocortex as the disease progresses.
Table 1  Characteristics of the 
neuropathological subsample, 
with and without dementia, of 
the Vantaa 85+ study
NFT neurofibrillary tangle, SN substantia nigra
a SN sample was missing from one participant
b DNA samples of 20 participants were not available (n = 284)
All participants 
(n = 304)
Dementia (n = 196) No dementia (n = 108)
Demographical details
 Sex (n, %)
  Men 52 (17) 30 (15) 22 (20)
  Women 252 (83) 166 (85) 86 (80)
 Age at death (mean ± SD) 92.4 (± 3.7) 92.5 (± 3.7) 92.1 (± 3.8)
 Age at death (n, %)
  85–89 82 (27) 46 (24) 36 (33)
  90–94 146 (48) 101 (52) 45 (42)
  ≥ 95 76 (25) 49 (25) 27 (25)
Neuropathological details
 Braak NFT stage (n, %)
  0–II 90 (30) 46 (24) 44 (41)
  III–IV 142 (47) 84 (43) 58 (54)
  V–VI 72 (24) 66 (34) 6 (6)
 CERAD score (n, %)
  None 71 (23) 33 (17) 38 (35)
  Sparse 33 (11) 17 (9) 16 (15)
  Moderate–frequent 200 (66) 146 (75) 54 (50)
SN neuron loss (n, %)a
  None 7 (2) 3 (2) 4 (4)
  Mild 161 (53) 98 (50) 63 (58)
  Moderate 115 (38) 76 (39) 39 (36)
  Severe 20 (7) 19 (10) 1 (1)
Genetic characteristics
 APOE ε4b (n, %)
  No 194 (68) 112 (61) 82 (83)
  Yes 90 (32) 73 (39) 17 (17)
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(B) Amygdala-based pattern was defined by the strongest 
pathology in the amygdala or in limbic area and propa-
gation to both caudal (brainstem, medulla and spinal 
cord) and rostral neocortical regions.
(C) One subject could not be categorized as every brain 
region was scored as very severe.
Statistical analyses
The stability of the LRP scored by the systematic anatomical 
scoring was then assessed using an unsupervised K-means 
classification method [22]. Although K-means does not ena-
ble direct validation of the results, it gives visual cues for the 
hard-to-classify samples, and aids analysts in their classifi-
cation efforts. Association between variables, such as LRP 
progression pattern, Braak NFT stage, CERAD score, APOE 
ε4, and gender was assessed using Fisher’s exact test. Means 
of continuous variables between two groups were compared 
using t test. If there were several groups to compare, a linear 
regression model was used. All statistical analyses were per-
formed in R version 3.6.0 (R Core Team 2019 R: A language 
and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria. URL https ://www.R-
proje ct.org/).
Ethics
The Vantaa 85+ study was approved by the Ethics Commit-
tee of the Health Centre of the City of Vantaa, and by the 
Coordinating Ethics Committee of the Helsinki and Uusimaa 
Hospital District. The Finnish Health and Social Ministry 
permitted the use of health and social work records and 
death certificates. The National Authority for Medicolegal 
Affairs (VALVIRA) approved the collection of the tissue 
samples and their use for research. The study participants 
or their relatives gave informed consent for blood sample 
collections and clinical evaluations. A written consent for 
each autopsy was obtained from the next of kin [37].
Results
Of the neuropathologically examined subsample (n = 304), 
LRP was present in at least one of the scored areas in 124 
subjects (41%), while 180 individuals had no LRP. When 
present, LRP was most frequently observed in the medulla 
(n = 113) and the substantia nigra (n = 106), and most infre-
quently in the parietal cortex region (n = 43) (Fig. 1).
DLB Consortium classification
After minor adjustments to the DLB Consortium guidelines 
(see Supplemental material for detailed description), we 
could classify 113/124 (91%) individuals into LRP classifi-
cation types; 19 were brainstem, 10 amygdala-predominant, 
41 limbic, and 43 diffuse neocortical type (Table 2). One 
subject showed, in addition to limbic type of α-synuclein 
pathology, strong oligodendroglial α-synuclein pathology 
compatible with multiple system atrophy. 11 (9%) individu-
als could not be classified into DLB Consortium types. They 
showed LRP confined in the pons, medulla and/or spinal 
cord, and no LRP was found in other brain regions. In addi-
tion, their neuron loss score in the substantia nigra was at 
most mild (Table 3).
LRP progression patterns
Based on LRP scores and LRP classification types, we next 
studied if individuals could fit consistently to the previously 
hypothesized caudo-rostral and amygdala-based progression 
patterns by systematic anatomical scoring. From the 124 
individuals with LRP, 83 (67%) showed caudo-rostral pro-
gression and 40 (32%) showed amygdala-based progression. 
In the whole population 27% showed LRP with caudo-rostral 
and 13% with amygdala-based progression pattern. One indi-
vidual had the highest LRP stage 4 in all brain regions and 
the progression pattern could not be determined (Table 3).
K-means cluster analysis classified individuals into nine 
clusters that matched the hypothesis of caudo-rostral and 
amygdala-based LRP progression. The result with nine clus-
ters was judged optimal using the “elbow method” [22]. Five 
clusters (n = 69) showed the strongest LRP at the spinal and 
brainstem level with decreasing LRP towards the limbic and 
cortical areas corresponding to the caudo-rostral LRP pro-
gression. Three clusters (n = 46) had the strongest LRP in the 
amygdala or limbic areas with decreasing pathology towards 
both the spinal-brainstem and cortical regions correspond-
ing to the amygdala-based progression pattern. One cluster, 
formed by eight individuals, could not be classified (Fig. 2).
Overall, the K-means cluster analysis and the systematic 
anatomical scoring classified 90% into same groups, show-
ing marked concordance between these analyses. Systematic 
anatomical scoring was used as the final results.
Overlap of the DLB consortium classification 
and LRP progression
The overlap of the DLB consortium LRP types and LRP pro-
gression patterns is shown in Table 2. Nearly all individuals 
(95%) of the brainstem type had the caudo-rostral progres-
sion pattern, and all of the amygdala-predominant type had 
the amygdala-based progression pattern. 58% of individuals 
with the diffuse neocortical and 71% of the subjects with 
limbic LRP type had the caudo-rostral progression pattern, 
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but both types also had a relatively high proportion (40% 
and 29%) of subjects with the amygdala-based progression 
pattern.
Spinal cord pathology and progression patterns
The distributions of spinal LRP are shown in Fig. 1. As 
expected, spinal cord pathology was predominantly 
Fig. 1  Distribution and density of Lewy-related pathology in the 
investigated brain regions. a, b Caudo-rostral n = 83 and c, d amyg-
dala-based n = 40 progression patterns visualized (y-axis) by quan-
tity (n) and percentage (%). Mean values (SD) of the investigated 
brain regions are shown in Supplemental Table  4. Spinal S = sacral 
spinal cord, spinal Th = thoracic spinal cord, sn = substantia nigra, 
amy = amygdala, ca2 = ca2 of hippocampus, tox = transentorhinal cor-
tex of hippocampus, cing = cingulate cortex, temp = temporal cortex, 
front = frontal cortex, pariet = parietal cortex, 1 = mild, 2 = moderate, 
3 = severe, 4 = very severe Lewy-related pathology
Table 2  The LRP progression patterns compared to the DLB Consortium classification [27] of the neuropathological subsample of the Vantaa 
85+ Study (n = 304a)
LRP Lewy-related pathology, DLB dementia with Lewy bodies
a Hippocampal samples from the right hemisphere were missing from 2 participants and were substituted with the left hemisphere samples; both 
spinal cord samples were missing from 1 participant, sacral spinal cord sample from 1 participant and SN sample from 1 participant
b One subject had highest LRP stage in all brain regions and the progression pattern could not be determined
DLB Consortium classification
None n = 180 Non-classifi-
able n = 11
Brainstem 
n = 19
Amygdala-pre-
dominant n = 10
Limbic n = 41 Diffuse neocortical 
n = 43
LRP progression  patternsb
 None n = 180 (59%) 180 (100)
 Caudo-rostral pattern n = 83 (27%) 11 (100) 18 (95) 0 (0) 29 (71) 25 (58)
 Amygdala-based pattern n = 40 (13%) 0 (0) 1 (5) 10 (100) 12 (29) 17 (40)
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Table 3  Characteristics of the neuropathological subsample of the Vantaa 85+ Study n = 304a categorized by (a) DLB Consortium classification 
[27], (b) LRP progression-based classification
Severe AD pathology (Braak NFT and CERAD score) and APOE ε4 are significantly more common in subjects with the amygdala-based pro-
gression pattern compared to those with caudo-rostral pattern or individuals with no LRP
LRP Lewy-related pathology, DLB dementia with Lewy bodies, NFT neurofibrillary tangles, SN substantia nigra
a Hippocampal samples from the right hemisphere were missing from 2 participants and were substituted with the left hemisphere samples; both 
spinal cord samples were missing from 1 participant, sacral spinal cord sample from 1 participant and SN sample from 1 participant
b One subject could not be classified because all regions obtained highest score and was excluded
c Modified NIA-RI neuropathological AD defined by [36] n = 173
d Excluded 1 participant without SN sample
e missing age at onset and duration of dementia values from 3 participants
f DNA samples of 20 participants were not available, n = 284
Negative LRP Positive LRP (Lewy-related pathology) n = 124
(a) DLB Consortium classification [27] n = 124 (b) LRP progression-
based n = 123b
No n = 180 Non-
classifiable 
n = 11
Brainstem n = 19 Amygdala-
predominant 
n = 10
Limbic n = 41 Diffuse 
Neocortical 
n = 43
Caudo-
rostral 
n = 83
Amygdala-
based 
n = 40
Women (%) 85 82 84 90 80 74 76 88
Mean age at death 
(years)
92.3 91.3 93.8 93.0 92.3 92.2 92.6 92.3
Age at death (n, %)
 85–89 45 (25) 5 (46) 4 (21) 1 (10) 14 (34) 13 (30) 26 (31) 11 (28)
 90–94 94 (52) 3 (27) 9 (47) 6 (60) 16 (39) 18 (42) 33 (40) 18 (45)
 ≥ 95 41 (23) 3 (27) 6 (32) 3 (30) 11 (27) 12 (28) 24 (29) 11 (28)
Braak NFT stage (n, %)
 0-II 54 (30) 6 (55) 8 (42) 1 (10) 10 (24) 11 (26) 34 (41) 2 (5)
 III–IV 92 (51) 3 (27) 8 (42) 5 (50) 20 (49) 14 (33) 36 (43) 13 (33)
 V–VI 34 (19) 2 (18) 3 (16) 4 (40) 11 (27) 18 (42) 13 (16) 25 (63)
CERAD score (n, %)
 None 46 (26) 2 (18) 7 (37) 1 (10) 11 (27) 4 (9) 24 (29) 1 (3)
 Sparse 24 (13) 1 (9) 3 (16) 0 (0) 3 (7) 2 (5) 9 (11) 0 (0)
 Moderate–frequent 110 (61) 8 (73) 9 (47) 9 (90) 27 (66) 37 (86) 50 (60) 39 (98)
NIA-RIc (n, %)
 No 32 (35) 3 (50) 7 (58) 0 (0) 7 (26) 4 (13) 21 (25) 0 (0)
 Yes 59 (65) 3 (50) 5 (42) 7 (100) 20 (74) 26 (87) 24 (29) 36 (90)
SN neuron  lossd (n, %)
 None 6 (3) 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 1 (3)
 Mild 115 (64) 11 (100) 9 (47) 5 (50) 16 (39) 5 (12) 36 (43) 10 (25)
 Moderate 54 (30) 0 (0) 8 (42) 5 (50) 20 (49) 28 (65) 36 (43) 25 (63)
 Severe 4 (1) 0 (0) 2 (11) 0 (0) 4 (10) 10 (23) 11 (13) 4 (10)
Dementia status at death (n,  %)
 No 74 (41) 5 (45) 10 (53) 1 (10) 15 (37) 3 (7) 31 (37) 3 (8)
 Yes 106 (59) 6 (55) 9 (47) 9 (90) 26 (63) 40 (93) 52 (63) 37 (93)
Age at dementia  onsete 87.2 86.5 88.5 88.1 88.4 86.0 88.5 85.3
Duration of dementia 5.2 5.6 4.8 5.3 4.3 6.1 4.2 6.9
APOE ε4f (n, %)
 No 126 (74) 7 (70) 15 (79) 5 (56) 19 (53) 22 (55) 54 (65) 13 (33)
 Yes 44 (26) 3 (30) 4 (21) 4 (44) 17 (47) 18 (45) 24 (29) 22 (55)
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associated with caudo-rostral progression pattern (Fisher’s 
test p = 0.007219). Out of 83 subjects with caudo-rostral pro-
gression pattern, 69 (83%) had detectable spinal LRP, and 
severe or very severe spinal LRP was present in 45 subjects 
(54%). Out of 40 subjects with amygdala-based progression 
pattern, 24 (60%) had any spinal LRP, but severe or very 
severe spinal LRP (classes 3 or 4) was present in only 6 
subjects (15%).
Demographic characteristics, dementia, and LRP 
progression patterns
There were slightly more men in the caudo-rostral progres-
sion pattern group compared to the amygdala-based progres-
sion pattern group (24% vs. 12%), but the difference was not 
statistically significant (Fisher’s test, p = 0.1576). The mean 
age at death did not show significant differences (p = 0.7256) 
between the amygdala-based (92.3 years), caudo-rostral 
(92.6 years) or no LRP (92.3 years) groups (Table 3).
There were significantly more people with dementia 
in the amygdala-based progression pattern group than in 
Fig. 2  Classification of individuals by the progression pattern of 
LRP by K-means cluster analysis. On the y-axis is the semiquanti-
tative LRP score (0–4). On the x-axis are the different CNS regions 
from spinal cord to neocortex: 1 = sacral spinal cord, 2 = thoracic spi-
nal cord, 3 = medulla, 4 = pons, 5 = substantia nigra, 6 = amygdala, 
7 = ca2 of hippocampus, 8 = transentorhinal cortex of hippocam-
pus, 9 = cingulate cortex, 10 = temporal cortex, 11 = frontal cor-
tex, 12 = parietal cortex. Clusters 1, 2, 3, 5 and 6 include individu-
als with caudo-rostral LRP progression pattern. Clusters 7, 8 and 9 
include individuals with amygdala-based progression pattern Cluster 
4 includes most severe LRP progression pattern from both caudo-ros-
tral and amygdala-based patterns
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the caudo-rostral group (Fisher’s test, p = 0.0004478) or 
in individuals with no LRP (Fisher’s test, p = 0.000018). 
The mean age of onset of dementia was 3.3 years lower 
in the amygdala-based than in the caudo-rostral progres-
sion pattern group (85.3 vs. 88.5 years, p = 0.003192), but 
the average survival time after the onset of dementia was 
almost 3 years longer in the amygdala-based pattern group 
(p = 0.0007487). Similar trend was seen when subjects 
with amygdala-based progression pattern were compared 
with individuals with no LRP (age at onset of dementia, 
p = 0.05216; duration of dementia, p = 0.01992). When 
comparing the caudo-rostral pattern group with individu-
als without LRP, there were no significant differences in 
the duration of dementia (p = 0.09785) or at the age at 
onset of dementia (p = 0.06853).
AD pathology and LRP progression patterns
The amygdala-based progression pattern was strongly 
associated with AD pathology (data shown in Table 3). 
Severe Braak NFT stage (V–VI) was more common in 
individuals with the amygdala-based progression than in 
those with the caudo-rostral progression (Fisher’s test, p 
value 0.00000005632) or with no LRP (Fisher’s test, p 
value = 0.0000001051). High CERAD score (moderate to 
frequent) was also more common in individuals with the 
amygdala-based progression than in those with the caudo-
rostral progression (Fisher’s test, p value = 0.00001861) or 
with no LRP (Fisher’s test, p value = 0.000006906). There 
was no difference in severe Braak NFT stage (Fisher’s test, 
p value = 0.2306) or high CERAD score (Fisher’s test, p 
value = 0.7622) between the caudo-rostral pattern group 
(n = 83) and individuals with no LRP (n = 180).
Of the 119 subjects with neuropathological AD defined 
by modified NIA-RI criteria [36] 60 (50%) showed LRP 
pathology. Of those 36 (60%) exhibited amygdala-based 
progression pattern, and 24 (40%) caudo-rostral progres-
sion pattern. When counted from 119 subjects with neu-
ropathological AD, 30% had amygdala-based and 20% 
caudo-rostral progression pattern of LRP.
APOE ε4 and LRP progression patterns
APOE ε4 was associated with the amygdala-based pro-
gression pattern, when comparing with the caudo-rostral 
progression pattern (Fisher’s test, p = 0.001843) or indi-
viduals with no LRP (Fisher’s test, p = 0.00004611, data 
shown in Table 3). No significant association with APOE 
ε4 was found, when the caudo-rostral pattern and individu-
als with no LRP were compared (Fisher’s test, p = 0.4457).
Discussion
Despite the fact that DLB was discovered as a disease 
entity already 35 years ago, many questions still remain 
to be solved concerning its pathology, genetics, and clini-
cal characteristics. Common challenges in DLB research 
include unclear overlap between DLB, AD and PDD, het-
erogeneity of DLB genetic risk factors, and a shortage of 
population-based studies, which can assess neuropathol-
ogy and genetics in a population at large [12, 16, 20, 26, 
45, 46]. To address some of these challenges, we investi-
gated LRP in a population-based setting using a wide dis-
tribution of tissue samples from spinal cord to neocortical 
areas without any hierarchical selections. In addition to 
the anatomical distribution, we investigated the progres-
sion patterns of LRP and its relation to AD pathology. 
We provide neuropathological and genetic evidence that 
two common progression patterns of LRP pathology exist 
in the very elderly population: the caudo-rostral pattern 
consistent with the generally accepted concept of LRP pro-
gression (67% of subjects with LRP), and the AD-associ-
ated amygdala-based pattern (32% of subjects with LRP). 
LRP with caudo-rostral or amygdala-based progression 
patterns were found in 27% and 13% of the whole popula-
tion, respectively, thus these pathologies represent very 
common neuropathologies in the very elderly population.
DLB Consortium classification and LRP progression 
patterns
This study updates our previous analysis of DLB Con-
sortium LRP types in the Vantaa 85+ sample, which was 
based on hierarchical selection of selected brain areas and 
the use of a less sensitive and specific α-synuclein anti-
body [33]. In the present study, we assessed LRP in 11 
anatomical sites with a more sensitive antibody [24, 25] 
but the results of neocortical areas did not change our pre-
vious classification of 43 subjects with neocortical type. 
However, 11 subjects (9%) with minimal pathology in the 
medulla were regarded as unclassified, when using the 
DLB Consortium guidelines. Another population-based 
study (CFAS) reported that a number of subjects could not 
be classified according to the DLB Consortium guidelines 
[47]. They found 8% of the subjects to have exclusively 
neocortical LRP, whereas we did not find any subjects with 
neocortical LRP without LRP in other brain areas.
When using our guidelines (systemic anatomical scor-
ing) according to progression patterns, only one subject 
(1%) could not be categorized. This one individual had 
severe LRP in all examined brain areas, and thus it was not 
possible to determine the progression pattern of LRP. It 
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is of note that those 11 subjects unclassified according to 
the DLB Consortium guidelines could be classified based 
on our progression pattern guidelines (systemic anatomi-
cal scoring). We hypothesize that these subjects actually 
represent individuals in the early stage of caudo-rostral 
progression pattern.
Nearly all individuals with the brainstem-predominant 
type according to the DLB Consortium guidelines showed 
the caudo-rostral progression pattern, as would be expected 
based on the PD staging by Braak et al. [6]. The limbic 
and diffuse neocortical LRP types were mixed, particu-
larly the diffuse neocortical LRP type (Table 2). Subjects 
with diffuse neocortical LRP type have abundant LRP in 
most brain areas, and thus categorization of the progres-
sion type is challenging. As expected, all subjects classified 
as amygdala-predominant type showed the amygdala-based 
progression pattern. We hypothesize that the subjects classi-
fied as amygdala-predominant type represent individuals in 
the early stage of the amygdala-based progression pattern. 
Our cohort consists of very elderly individuals, most of them 
showing dense and widely distributed LRP load accumu-
lated possibly during a long time period, and this may have 
enabled us to observe two distinct progression patterns.
Association of amygdala‑based progression 
with dementia and survival
In our study, 93% of subjects were with amygdala-based 
LRP pattern whereas 63% of subjects with caudo-rostral pat-
tern were diagnosed with dementia. The mean age at onset 
of dementia was 3.3 years earlier in the amygdala-based 
pattern than in the caudo-rostral pattern, possibly reflecting 
multipathology, i.e., concomitant AD and LR pathologies 
in the limbic areas. Interestingly, the mean survival after 
dementia was 2.7 years longer in the amygdala-predominant 
versus caudo-rostral pattern and, thus the mean age at death 
did not differ significantly. Previous population-based stud-
ies have not investigated possible associations of dementia, 
survival, and progression patterns.
Association of the progression types with AD 
pathology
The strong association between the amygdala-based pattern 
and AD pathology is in accordance with previous studies 
[2, 11, 18, 34, 41, 43]. In our sample, any LRP was found in 
50% of subjects with neuropathological AD, which is in line 
with both population and non-population-based studies [2, 
18, 21, 38, 43]. Of the subjects with neuropathological AD 
in this study, 30% showed amygdala-based and 20% caudo-
rostral progression pattern. These figures are somewhat dif-
ferent to those found in the previous study by Uchikado et al. 
[43] focused on cases of AD, where 18% had AD/amygdala 
Lewy body pathology and a few more (25%) had a pattern 
resembling caudo-rostral progression. However, both study 
design and neuropathological classification scheme were dif-
ferent in this study compared to ours, and hence these stud-
ies are not directly comparable. Interestingly, in the present 
study both progression patterns of LRP were common in 
the diffuse neocortical LRP type; 40% had the amygdala-
based and 58% showed the caudo-rostral progression pat-
tern. Whether this could explain some clinical variation of 
DLB, needs to be investigated in future studies.
Association of APOE ε4 and the amygdala‑based 
progression pattern
The clear dichotomous association of the APOE ε4 carrier 
status with the amygdala-based progression strongly sup-
ports the existence of a biologically distinct AD-associated 
LRP type. APOE has been the strongest and the most rep-
licable finding in genetic studies of DLB [4, 7, 17, 40, 42]. 
However, the associations between DLB and APOE ε4 have 
been weaker than those found between APOE ε4 and AD 
[15, 35, 42]. In our previous study, an association between 
APOE ε4 and neocortical LRP was found but lost its sig-
nificance when AD pathological variables were included in 
the multiple regression model [35], indicating no independ-
ent association between LRP and APOE ε4. In light of the 
present results, the APOE ε4 association in the Vantaa 85+ 
and in the other data sets reported thus far may be driven 
by subjects with amygdala-based LRP with concomitant 
AD pathology. Our population-based data are in somewhat 
contrast to a recent large study by Dickson et al., based on a 
material from a referral-based institution [9], where subjects 
with low AD pathology were divided into groups, of which 
“diffuse Lewy body disease” (n = 33, median Braak NFT 
stage III, Thal phase 1) was associated significantly with 
APOE ε4, while no association was found in “transitional 
Lewy body disease” (n = 46, median Braak NFT stage II, 
Thal phase 1). It is noteworthy that the previously reported 
“pure DLB” of the Vantaa 85+ material [33] (comparable 
to the “diffuse Lewy body disease” group reported by Dick-
son et al.) was not associated with APOE ε4 (Supplemental 
Table 3). Moreover, the material of the study by Dickson 
et al. was referral-based, younger and with a male predomi-
nance, while in the Vantaa 85+ there were only 24% males 
in the caudo-rostral and 12% in the amygdala-based patterns.
Strengths and limitations of the study
The strengths of the study include its population-based 
nature and relative genetic and cultural homogeneity of the 
Finnish population. The specific antibody clone 5G4 was 
used in this study, because it has been shown to work well 
even in preserved samples with long fixation times [25]. 
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We used an objective statistical tool, the K-means analy-
sis, to identify different patterns of LRP progression. We 
compared the results of the K-means analysis with those 
of the systematic anatomical scoring and found 90% con-
cordance between the results. On the other hand, our study 
population was selected by age, and this should be noticed, 
when comparing our results with other studies. A limita-
tion of the study is the semiquantitative LRP scoring, which 
is somewhat subjective and may potentially influence the 
results. There was only limited clinical Parkinsonism data 
available in our data set (Supplemental Table 5), as the clini-
cal assessment of the very elderly people was challenging, 
and thus the clinical significance of progression types could 
not be comprehensively investigated here. Furthermore, we 
were not able to study olfactory bulb and nucleus basalis of 
Meynert since they were not included in the original post-
mortem sampling protocol. Population-based studies assess-
ing LRP in the olfactory bulb are currently lacking in the 
literature, but are warranted as they might reveal invaluable 
insights into the early development of LRP in DLB [8]. In 
the future, LRP should perhaps be quantified continuously 
using computational methodology as has been done with 
tau pathology [31].
Conclusion
Our population-based data provide strong neuropathologi-
cal and genetic evidence that two progression patterns of 
LRP exist in an elderly population: the caudo-rostral pattern 
consistent with the generally accepted concept of LRP pro-
gression and AD- and APOE ε4-associated amygdala-based 
pattern. Our results support the view that AD-associated 
amygdala-based LRP is a distinct α-synucleinopathy and 
we show for the first time in a population-based setting that 
it is common among the very elderly: it was found in 13% of 
the whole population, in 32% of the subjects with LRP and 
in 30% of the subjects with neuropathological AD.
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